New Milestone - Moxidectin NDA to treat River Blindness registration in FDA
2018/1/3 view:
Breaking news: under our support on API moxidectin supply, DMF filing and US FDA audit, our client from Australia, a not for profit biopharmaceutical company, has submitted a New Drug Application to the FDA for moxidectin for the treatment of river blindness. Our client received funding for this project from the Global Health Investment Fund which is backed by the Bill and Melinda Gates Foundation, and has a mandate to supply moxidectin to those in need, mainly in Africa. This important submission will help our company to be the leading supplier of moxidectin so we look forward to many more business opportunities.
- Pre：Zjpharma Assisted Chongqing So 2018/1/25
- Next：Welcome to Supplyside West 201 2017/11/14
